Most Recent
Neurim’s claim for additional damages survives in Circadin patent case
Intellectual Property 2024-06-03 11:48 pm By Sam Matthews

A judge has upheld Neurim Pharmaceutical’s claim for additional damages against two generic drug companies found to have infringed its patent for insomnia drug Circadin, despite the company’s failure to comply with an earlier ruling.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

After 7 years of litigation, patent for blockbuster sleep drug Circadin found valid
Intellectual Property 2024-04-18 11:21 pm By Sam Matthews

After a seven-year legal battle, a court has upheld the validity of Neurim Pharmaceutical’s patent for insomnia drug Circadin and ruled two generic drug companies infringed the intellectual property.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Zoetis can appeal Boehringer win over pig vaccine patents
Intellectual Property 2024-03-26 4:25 pm By Christine Caulfield

US animal drug manufacturer Zoetis has been granted leave to appeal a ruling that invalidated three of its patents covering pig vaccines.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Court hands win to Boehringer in fight over Zoetis vaccine patents
Intellectual Property 2023-10-03 11:51 pm By Sam Matthews

German drug maker Boehringer has prevailed in its Federal Court fight against US rival Zoetis over the validity of three patents covering pig vaccines.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Novartis, Pharmacor resolve suit over Gilenya patents
Intellectual Property 2022-11-14 1:42 pm By Cat Fredenburgh

Novartis and and generic drug maker Pharmacor have resolved litigation over the Swiss pharmaceutical giant’s patents for blockbuster MS drug Gilenya.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Biogen, Pharmacor lay down swords in battle over MS drug patent
Intellectual Property 2022-10-31 11:01 pm By Cat Fredenburgh

Swiss pharmaceutical company Biogen and Australian generic drug maker Pharmacor have dropped their claims against one another in a lawsuit over the patent for MS drug Tecfidera. In an October 14 order by Federal Court Justice Helen Rofe, Biogen’s infringement claims and Pharmacor’s cross-claims seeking to invalidate the lucrative patent were discontinued by consent without […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Novartis can’t appeal loss of experts in MS drug patent feud with Pharmacor
Intellectual Property 2022-04-07 12:29 pm By Christine Caulfield

The Full Federal Court won’t give Swiss pharmaceuticals giant Novartis the chance to appeal a ruling that threw out three of its four experts in a patent case against generic drug maker Pharmacor.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Novartis challenges loss of experts in spat with Pharmacor over generic Gilenya
Intellectual Property 2022-03-28 3:25 pm By Christine Caulfield

Novartis wants to appeal a ruling in its dispute with generic drug maker Pharmacor over patents for its multiple sclerosis drug Gilenya that tossed three of its four experts out of an upcoming so-called hot tub.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Judge tosses Novartis experts out of ‘hot tub’ in MS drug patent dispute
Intellectual Property 2022-03-18 5:54 pm By Miklos Bolza

A judge has slammed Novartis for putting forward four “overlapping” experts in a dispute with Pharmacor over patents for its MS drug Gilenya and thrown three of those experts out of an upcoming joint conferral, known as a “hot tub”.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Pharmacor challenges patent extension for Biogen’s MS drug
Intellectual Property 2021-09-23 2:14 pm By Bianca Hrovat

An Australian generic drug manufacturer has struck back at patent lawsuit by Swiss pharmaceutical company Biogen, alleging a patent for MS drug Tecfidera is invalid and a that a patent term extension for the drug  was wrongly granted.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.